Taken together with our results showing that inhibition of Aurora B leads to enhanced sensitivity to eribulin, this indicates that MT-destabilizing agents, such as vinblastine, vincristine, vinorelbine, and eribulin, may be more appropriate than MT-stabilizing agents, such as taxans and epothilones, for treating cancer cells with a weakened SAC. This evidence concerns the gene AURKB and cancer.